| Literature DB >> 27528434 |
Hao Zhou1, Xin Che1, Guochen Bao1, Na Wang1, Li Peng1, Kimberly D Barnash2, Stephen V Frye2, Lindsey I James3, Xu Bai4.
Abstract
Epigenetic alterations relate to various human diseases, and developing inhibitors of Kme regulatory proteins is considered to be a new frontier for drug discovery. We were inspired by the known multicyclic ligands, UNC669 and UNC926, which are the first reported small molecule ligands for a methyl-lysine binding domain. We hypothesized that reducing the conformational flexibility of the key amine moiety of UNC669 would result in a unique set of ligands. Twenty-five novel compounds containing a fused bi- or tricyclic amine or a spirocyclic amine were designed and synthesized. To gauge the potential of these amine-containing compounds to interact with Kme regulatory proteins, the compounds were screened against a panel of 24 protein methyltransferases. Compound 13 was discovered as a novel scaffold that interacts with SETD8 and could serve as a starting point for the future development of PKMT inhibitors.Entities:
Keywords: Cross-screening; Cyclic fused and spirocyclic amines; Histone methyltransferases; Structure based design
Mesh:
Substances:
Year: 2016 PMID: 27528434 PMCID: PMC4996710 DOI: 10.1016/j.bmcl.2016.08.004
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823